Skip to main content
main-content

Video commentaries

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Expert commentaries on the latest practice-influencing developments from international congresses.


AACR Annual Meeting 2019

02-04-2019 | Immunotherapy | Video | Article

Researcher comment: The impact of lifestyle factors on the gut microbiome and immunotherapy response

Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).

02-04-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: Liquid biopsy noninferior to tissue biopsy for identifying genomic targets in metastatic NSCLC

Researcher Vassiliki Papadimitrakopoulou describes the findings of the prospective NILE study evaluating the clinical utility of genotyping cell-free DNA in patients with a new diagnosis of metastatic non-small-cell lung cancer (3:21).

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

ESMO 2018 Congress

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

30-10-2018 | Colorectal cancer | ESMO 2018 | Video

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC

Heinz-Josef Lenz outlines the results of CheckMate-142 study investigating combination immunotherapy in the first-line treatment of patients with MSI-high metastatic colorectal cancer, and discusses the unmet needs of those with MSI-low tumors (5:58).

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial

ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

24-10-2018 | Tamoxifen | ESMO 2018 | Video

Serum analysis sheds light on tamoxifen adherence

Barbara Pistilli discusses the CANTO COMPLETE study of premenopausal breast cancer patient adherence to endocrine therapy (4:31).

24-10-2018 | Breast cancer | ESMO 2018 | Video

Evaluating alpelisib addition to standard of care in SOLAR-1

We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

23-10-2018 | Ovarian cancer | ESMO 2018 | Video

SOLO1 trial of maintenance olaparib in advanced ovarian cancer

SOLO1 co-author Susana Banerjee provides a quick take on the study findings and discusses the challenges going forward (3:55).

22-10-2018 | Non-small cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

View more videos

Image Credits